Last reviewed · How we verify

Flubuperone — Competitive Intelligence Brief

Flubuperone (MELPERONE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: melperone. Area: Other.

discontinued melperone D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1D Other Small molecule Live · refreshed every 30 min

Target snapshot

Flubuperone (MELPERONE). Flubuperone works by selectively blocking the D(3) dopamine receptor, which helps regulate mood and emotional responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Flubuperone TARGET MELPERONE discontinued melperone D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1D

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (melperone class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flubuperone — Competitive Intelligence Brief. https://druglandscape.com/ci/melperone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: